How effective is ustekinumab for psoriatic arthritis?

In the treatment of active psoriatic arthritis, ustekinumab was compared with placebo in 2 major studies involving a total of 927 adult patients whose disease was not adequately controlled by prior treatments. In both studies, the primary measure of effectiveness was the number of patients whose symptom scores improved after 24 weeks. In the first study, approximately 42% of patients taking ustekinumab 45 mg and 90% taking ustekinumab 45 mg Symptom scores improved in 50% of patients taking mg, compared with about 23% of patients taking placebo. In the second study, symptom scores improved in about 44% of patients who took any dose of ustekinumab, compared with about 20% of those who took placebo. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.